RIO DE JANEIRO, BRAZIL – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces that a study carried out by Argentina’s Institute of Virology of the National University of Cordoba and the Government of Cordoba has confirmed the neutralization effectiveness of the Russian two-dose Sputnik V coronavirus vaccine against the Manaus (Brazilian) variant and overall strong immune response after vaccination with Sputnik V.
The study specifically confirmed that the immunity generated thanks to vaccination with Sputnik V neutralizes the Manaus (Brazilian) variant in those who received one dose as well as subjects inoculated with two doses of the vaccine.
The study also demonstrated that:
99.65% of subjects induced IgG antibodies to COVID-19 on 42nd day after receiving the 2nd dose; and 85.5% of subjects induced IgG antibodies to COVID-19 on 14th day after receiving the 1st dose.
To date the Russian vaccine has been registered in 66 countries with total population of over 3.2 billion people. Post-vaccination studies in a number of countries demonstrate that Sputnik V is the safest and most effective vaccine against coronavirus. Sputnik V ranks second among coronavirus vaccines globally in terms of the number of approvals issued by government regulators.